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Background: It has been known for more than 100 years that aneuploidy is an essence of cancer. The question is
what keeps the genome stable, thereby preventing aneuploidy. For the past 25 years, it has been proposed that
p53 is the “guardian of the genome.” However, it has been shown that inactivation of p53 does not cause
aneuploidy. Another essence of cancer is global DNA hypomethylation, which causes destabilization of the genome
and subsequent aneupoloidy. Yet, another essence of cancer is excessive use of methionine, resulting in
methionine dependence. Methionine dependence is due to possible “metabolic reprogramming” due to
carcinogens, including chemical agents and infectious organisms, such as Helicobacter pylori, that result in altered
and excessive transmethylation in cancer cells. Cancer cells appear to have a “methyl-sink” whereby methyl groups
are diverted from DNA.
Conclusion: DNA hypomethylation destabilizes the genome, leading to aneuploidy and subsequent selection and
speciation into autonomous cancers, leading to the conclusion that DNA methylation is the “guardian of the
genome.”
Keywords: Methionine, Methionine dependence, Unbalanced transmethylation, Global DNA hypomethylation,
Chromosome instability, Aneuploidy, Cancer speciation
“E pur si muove” Galileo
Is p53 “the guardian of the genome”?
Since Lane designated p53 as the “guardian of the genome”
[1], this has become the dominant paradigm [2–4].
DNA hypomethylation in cancer
It has been long known that global DNA hypomethylation
is a general characteristic of cancer, as originally discov-
ered by our laboratory [5, 6]. DNA hypomethylation is an
early event in the formation of cancer as it appears in pre-
malignant tissue [7]. The progression of DNA hypomethy-
lation may be driven by “oncogenes” [8].
Hints regarding the effect of DNA hypomethylation on
genome integrity come from Perucho et al. [9] on the
relationship of Helicobacter pylori to gastric cancer.
Helicobacter pylori infection is a very important risk
factor for gastric cancer. Perucho et al. [9] observed that
H. pylori appears to cause a field defect of DNA hypo-
methylation in a region of the gastric mucosa prior to
cancer development that is not reversed by H. pylori
eradication. Perucho et al. [9] also observed that en-
hanced DNA hypomethylation, was associated with a
more invasive and advanced stage type of gastric cancer.
Other studies have indicated that the greater extent of
DNA hypomethylation, the more malignant is the
cancer. The total levels of DNA 5-methylcytosine were
determined in a series of highly metastatic cell lines
which had been isolated from a poorly metastatic human
melanoma tumor line, MeWo, by Kerbel’s group [10].
Similar to what was observed in gastric cancer described
above, the more metastatic the melanoma sublines were,
the more extensively they were hypomethylated [10].
It has also been shown that global DNA hypomethylation
increases as cervical dysplasia progresses to cervical
carcinoma [11].
Compared to benign tumors, atypical and malignant
meningiomas were observed to have increased global
DNA hypomethylation [12].
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DNA hypomethylation leads to aneuploidy
Jaenish et al. generated mice with a mutant DNA meth-
yltransferase 1 (DNMT1) allele. The mutation reduces
Dnmt1 expression to 10% of normal levels and results in
substantial genome-wide hypomethylation in all tested
tissues. The mutant mice developed T cell lymphomas
which had a high frequency of chromosome 15 trisomy.
DNMT-deficient HCT-116 colon cancer cells had a high
degree of genome instability leading to aneuploidy, in-
cluding many novel chromosomal translocations [13].
These results indicate that DNA hypomethylation plays
a causal role in chromosomal instability, aneuploidy, and
subsequent cancer [14].
Methionine
Methionine [15] is an essential amonio acid; however, it
can be synthesized from homocysteine [16] and methyl-
tetrahydrofolate [17, 18] in a vitamin B12-dependent
reaction. Methionine is a component of proteins. Me-
thionine is also the universal methyl donor via its
activated form S-adenosylmethionine [19].
Deprivation of methionine leads to cancer
Copeland and Salmon observed the development of liver,
lung, and other cancers in a significant percentage of
rats on a diet deficient in choline, which is a precursor
of methionine [20]. This was the first solid evidence that
methionine is involved in cancer [21].
Subsequently, Ghoshal and Farber observed that Fischer
344 male rats fed a choline-methionine deficient diet for
1–2 years during which the rats developed a 100% inci-
dence of preneoplastic hepatocyte nodules. Subsequently,
51% of the rats developed hepatocellular carcinoma. Sup-
plement of the diet with 0.8% choline chloride prevented
the development of both the precancerous nodules and
subsequent cancer [22].
The cancers resulting from methionine/choline-de-
prived diets in the rats were probably due to methyl
shortage and subsequent DNA hypomethylation, since
methionine is the source of methyl groups for DNA
methylation. DNA hypomethylation appears to be an
early event in choline/methionine-deficient diets, irre-
versible [23–26] and mediated by a deficiency in S-
adenosylmethionine [27].
Methionine dependence and altered
transmethylation in cancer
The appearance of cancer in rats on choline- and
methionine-deficient diets gave an early hint that per-
turbed methionine metabolism is involved in cancer.
Sugimura noted almost 60 years ago that rat tumor
growth was slowed by giving the rats a defined diet de-
pleted in methionine for a short period of time [28].
Approximately 45 years ago, it was observed that mouse
leukemia cells in culture required very high levels of
methionine in order to proliferate [29]. Subsequently,
most cancer cell lines were found to be methionine
dependent [30, 31]. These cell lines were derived from
various cancer types including liver, pancreatic ovarian,
submaxillary, brain, lung, bladder, prostate, breast, kidney,
cervical, colon, fibrosarcoma, osteosarcoma, rhabdomyo-
sarcoma, leiomyosarcoma, neuroblastoma, glioblastoma
and melanoma [30, 31]. Normal unestablished cell strains,
thus far characterized, grow well in methionine-depleted
medium [30, 32]. Many of the cancer cell lines tested have
little else in common other than the fact that they are
methionine-dependent and have altered methionine me-
tabolism [33]. Human patient tumors, including tumors of
the colon, breast, ovary, prostate, and a melanoma, were
also found to be methionine dependent in Gelfoam® histo-
culture [34]. The high frequency of occurrence of methio-
nine dependence in diverse types of human cancer cells
indicated that methionine dependence could be an im-
portant step in oncogenic transformation.
Three lines of evidence indicated that methionine-
dependent cancer cells synthesize large amounts of
methionine endogenously through the reaction catalyzed
by N5-methyltetrahydropteroyl-L-glutamate: L-homocyst-
eine S-methyltransferase (EC 2.1.1.13) [35].
 The activity of the methyltransferase involved in
methionine biosynthesis was comparable in extracts
of malignant and normal cells [35].
 The uptake of radioactive label from [5-14C]
methyltetrahydropteroyl-L-glutamic acid (N5-
methyl-H4PteGlu), the methyl donor for methionine
biosynthesis, was at least as great in the malignant
cells as in the normal cells and was nearly totally
dependent on the addition of homocysteine, the
methyl acceptor in methionine biosynthesis [33, 35].
 The majority of the labeled methyl groups incorporated
by cancer cells was recovered as methionine [35].
We subsequently observed that although methionine-
dependent cancer cells synthesized a normal amount of
methionine, the level of free methionine and S-
adenosylmethionine (AdoMET), which is synthesized
from methionine and is the universal methyl donor,
were very low in cancer cells in methionine (MET)-de-
pleted homocysteine (HCY)-supplemented medium
(MET−HCY+). In contrast, exogenously supplied MET
resulted in normal levels of AdoMET. The ratio of
AdoMET to S-adenosylhomocysteine (AdoHCY) is
low in methionine-dependent cancer cells growing in
MET−HCY+ medium, but is normal in MET+HCY−
medium. We determined that the low AdoMET/AdoHCY
ratio probably limits growth of MET-dependent cells in
MET−HCY+ medium [36, 37].
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We subsequently observed that cancer cells have
enhanced overall rates of transmethylation compared to
normal human fibroblasts (Fig. 1) [38]. Transmethyla-
tion rates were measured by blocking AdoHCY hydro-
lase and measuring AdoHCY, which accumulates as a
result of transmethylation from AdoMET. The excess
methionine used for the enhanced transmethylation
rates appears to be the basis of the methionine depend-
ence of cancer cells which explains the low levels of free
methionine and the low AdoMET/AdoHCY ratio in can-
cer cells under methionine deprivation [37, 38]. The ele-
vated methionine use in cancer cells has been termed
the “Hoffman effect” [39], analogous to the “Warburg
effect” for enhanced glucose utilization in cancer [40].
The alteration of such a fundamental process as trans-
methylation in cancer may be indicative of its import-
ance in the oncogenic process [32].
The abnormal elevated transmethylation and subsequent
depletion of AdoMET appears to result in hypomethylation
of DNA in cancer cells, since the methionine methyl group
may be diverted to a methyl sink in the cancer cells and
not sufficiently available for normal DNA methylation. For
example, when the W-256 cancer cell line was cultured for
24 h in MET−HCY+ medium, the extent of methylation of
nucleic acids and the acid-soluble pool of methionine
were decreased. However, there was increased methyla-
tion activity of both an endogenous substrate and
Escherichia coli tRNA. Methionine deprivation of the
W-256 cells resulted in a large increase in the Vmax
value for methylation of tRNA, without any change in
the Km value for AdoMET [41]. These results indicated
that methyl groups originating from methionine may be
diverted from DNA in cancer cells.
Rare cells from methionine-dependent cancer cell lines
regained the normal ability to grow in MET−HCY+
medium. These cell lines were termed methionine-
independent revertants. Two revertants isolated from
SV40-transformed cells had regained the ability to grow
similar to normal cells in MET−HCY+ medium without
substantial changes in methionine biosynthesis activity.
Increased methionine biosynthesis thus is not a pre-
requisite to reversion from methionine dependence to
independence [42, 43].
Methionine-independent revertants also had much
lower basal transmethylation rates than parental me-
thionine-dependent cell lines. For example, when
comparing the methionine-dependent parent SP1 cell
line and its methionine-independent revertant, the re-
vertant SP1-R reduced its transmethylation rate. These
results further suggested that methionine dependence
is due to an increase in the rate of transmethylation
reactions [44].
We then demonstrated that methionine-independent
revertants of cancer cells concomitantly revert for char-
acteristics associated with cancer. Of the 13 cancer-cell
methionine-independent revertants characterized, 5
showed increased anchorage dependence for growth as
reflected by reduced cloning efficiencies in methylcellu-
lose, 8 showed an increased serum requirement for op-
timal growth, 8 showed decreased cell density in
medium containing high serum, and 3 altered their cell
morphology significantly. Thus, the methionine-
independent revertants become more normal-like.
Eight of the 13 had increased chromosome numbers,
which probably played a role in reversion. Thus by
selecting for methionine independence, it is possible to
select for heterogeneous malignant-transformation re-
vertants, which became less malignant, indicating fur-
ther a relationship between altered methionine
metabolism and oncogenic transformation [43].
Growth arrest of methionine-dependent cancer cells in
MET−HCY+ medium resulted in a reduction in the per-
centage of mitotic cells in the cell population.
Fluorescence-activated cell cycle analysis demonstrated that
the cells are arrested in the S/G2 phases of the cell cycle in
MET−HCY+ medium. This is in contrast to a G1-phase ac-
cumulation of cells, which occurs only in methionine-
supplemented medium at very high cell densities and is
similar to the G1 block seen in cultures of normal fibro-
blasts at high density [45]. Depletion of methionine in vivo
by recombinant methioninase (rMETase) also resulted in S/
G2 cell cycle arrest in tumors (Fig. 2) [46].
Fig. 1 Recombinant methioninase (rMETase) traps cancer cells in S/G2
phase. Time-course imaging of HeLa-FUCCI cells treated with rMETase
(1.0 unit/ml). Kinetics of rMETase trapping of cells in S/G2. Images were
acquired with the FV1000 confocal microscope (Olympus, Tokyo, Japan).
In the FUCCI system, the cells in G0/G1, S, or G2/M phases appear
red, yellow, or green, respectively [66]
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In summary, the altered methionine metabolism and
transmethylation in cancer cells may be the initiating event
of DNA hypomethylation and subsequent aneuploidy.
Progression of aneuploid cells to autonomous
cancer
Duesberg et al. [47] have proposed that carcinogenesis,
such as that caused by SV40 virus, is due to induced an-
euploidy, which destabilizes the karyotype which pro-
gressively evolves to autonomous clonal cancers.
Duesberg et al. [48] proposed that other carcinogens
induce aneuploidy in cancer in a similar way. They in-
duced carcinogenesis with nitrosourea and observed
noninvasive mammary tumors after 2 or more months
and invasive carcinomas after 6 or more months. As
with SV40, these researchers observed that aneuploid
karyotypes, with varying non-clonal hyperplasias,
formed rare cancer “species” with individual clonal
karyotypes, which became autonomous cancers.
From perturbed methionine metabolism to DNA
hypomethylation to a destabilized genome to
aneuploidy to cancer
We suggest here that the pre-malignant DNA hypomethy-
lation such as that observed by Perucho et al. [9] results
from the unbalanced excess transmethylation which di-
verts methyl groups into where they are not available for
normal methylation processes such as DNA methylation.
The excess transmethylation rate explains the “methionine
dependence” of cancer cells. Hypomethylation of DNA
then results in the initiation of aneuploidy and subsequent
speciation to autonomous cancer.
Thus, we propose that carcinogenesis is initiated by
perturbation of methionine metabolism and transmethy-
lation (“metabolic reprogramming”) resulting in DNA
hypomethylation, thereby destabilizing the karyotype,
which sets off a chain reaction of aneuploidizations as
Duesberg proposes, which generate ever more abnormal
karyotypes and eventually cancer-specific combinations
[49]. It is possible that the degree of methionine depend-
ence of cancer cells, which may be influenced by their
extent of methionine biosynthesis from homocysteine,
may affect how much DNA hypomethylation has oc-
curred in cancer cells.
This hypothesis of cancer generation described in this
review can accommodate mutated “oncogenes,” “driver
genes,” “tumor suppressor genes,” etc., that may influence
the behavior of cancers. However, with possible rare ex-
ceptions, individual gene alterations do not account for
the global changes resulting in methionine dependence,
global DNA hypomethylation, and altered karotype evolu-
tion, all of which are the essences of cancer.
Every hypothesis should be testable and be able to be
negated. The present hypothesis for example predicts that
premalignant tissue such as observed in the stomach with
H. pylori infection or SV-40 infection, other infectious
agents such as human papiloma virus, Epstein-Barr virus
[50], or carcinogens such as nitrosourea or cigarette
smoke, should have an elevated methionine requirement
and excess and altered transmethylation leading to DNA
hypomethylation as shown in the stomach after H. pylori
infection by Perucho et al. [9]. The hypothesis predicts
that chronic perturbation of methionine metabolism
should be carcinogenic, such as a chronic methionine-
depleted diet. The hypothesis also predicts that short-term
Fig. 2 Efficacy of recombinant methioninase (rMETase) on growth of human colon tumors HCT 15 in nude mice. rMETase (5 or 10 units/g every
8 h) was administered by i.p. injection in nude mice with human colon tumor HCT 15, growing s.c. [54]
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deprivation of methionine should be curative to cancer
and in mouse models; this has shown to be the case (Fig. 3)
[35, 51–55]. However, important aspects of using methio-
nine deprivation to treat cancer still remains to be investi-
gated, including side effects on other metabolic pathways
as well as the influence of the extent of methionine-
synthesis capacity of cancer cells on the outcome of this
therapy.
The hypothesis also explains why the use of [11C] me-
thionine is so effective in positron emission tomography
(PET) imaging, since the cancers use excessive methio-
nine for their aberrant excess transmethylation and
therefore take up excess [11C] methionine. For example,
the higher specificity and sensitivity of [11C]-labeled me-
thionine in PET (MET-PET) such as in gliomas has been
demonstrated [56]. Because of these properties, MET-
PET is the most popular amino acid tracer used in PET
imaging of brain tumors and provides a high detection
rate of brain tumors and metastasis and accurate tumor
delineation [57]. MET-PET can also distinguish between
recurrent glioma and necrosis [58]. MET-PET was
heterogeneous in areas that MRI showed to be homoge-
neous, demonstrating the higher sensitivity of MET-
PET. Malignant histopathology was detected in the areas
of the tumor with the highest MET uptake, suggesting
higher MET uptake correlates to a higher degree of
malignancy consistent with our hypothesis [59]. MET-
PET also could distinguish cures in melanoma [60].
Conclusion
The current paradigm is that p53 is the “guardian of the
genome” [1–4, 61]. However, DNA methylation may be
a more global “guardian of the genome.” When DNA
methylation is disrupted by aberrant (“re-programmed”)
methionine metabolism, DNA becomes globally hypo-
methylated resulting in chromosome instability and
aneuploidy leading to possible “cellular speciation”
and clonal cancer [62].
It is hypothesized that carcinogens may have their ini-
tial effect by “reprogramming” methionine metabolism,
in particular transmethylation. Such carcinogens include
chemicals as well as infectious agents such as SV-40
virus and H. pylori. It is remarkable that all types of
cancers tested are found to be methionine dependent
[32], which is perhaps the only known general metabolic
abnormality in cancer [63]. This methionine metabolism
“reprogramming” results in global [5, 6] and gene-
specific [64] DNA hypomethylation, another general de-
fect in cancer, which in turn leads to aneuploidy, another
general defect in cancer which in turn leads to cancer
“speciation.” Vogelstein et al. [65] reported that inactiva-
tion of p53 did not lead to aneuploidy. Thus, it seems
that the genome has another “guardian”, DNA methyla-
tion is a likely candidate, and when it is perturbed, the
genome destabilizes leading to aneuploidy and cancer
[14]. Please see (Additional file 1).
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Fig. 3 Rates of transmethylation of human tumor cell lines and normal
human fibroblast cell strains. All cells were labeled with 100 μM [35S]-
methionine-containing medium (25 μCi/ml) for 24 h. Periodate-
oxidized 3-deazaadenosine was added to a concentration of 10 pM
and the accumulation of [35S] AdoHcy was measured at half- hour in-
tervals. Solid lines are human cancer cell lines. Dashed lines are human
normal cell strains [38]
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